Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Inhibition of iron uptake is responsible for differential sensitivity to V-ATPase inhibitors in several cancer cell lines.

Straud S, Zubovych I, De Brabander JK, Roth MG.

PLoS One. 2010 Jul 16;5(7):e11629. doi: 10.1371/journal.pone.0011629.

2.

Increased production of reactive oxygen species by the vacuolar-type (H(+))-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells.

Yokomakura A, Hong J, Ohuchi K, Oh SE, Lee JY, Mano N, Takahashi T, Hwang GW, Naganuma A.

J Toxicol Sci. 2012;37(5):1045-8.

3.

V-ATPase inhibitors and implication in cancer treatment.

Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JM, García-García A.

Cancer Treat Rev. 2009 Dec;35(8):707-13. doi: 10.1016/j.ctrv.2009.08.003. Epub 2009 Sep 15. Review.

PMID:
19758758
4.

Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer.

Hernandez A, Serrano-Bueno G, Perez-Castineira JR, Serrano A.

Curr Pharm Des. 2012;18(10):1383-94. Review.

PMID:
22360554
5.

Archazolid and apicularen: novel specific V-ATPase inhibitors.

Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, Zeeck A, Wieczorek H.

BMC Biochem. 2005 Aug 4;6:13.

6.

pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines.

Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ.

Biochem Pharmacol. 1999 May 1;57(9):1037-46.

PMID:
10796074
7.

Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.

Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, Trauner D, Menche D, Vollmar AM.

Cancer Res. 2015 Jul 15;75(14):2863-74. doi: 10.1158/0008-5472.CAN-14-2097. Epub 2015 May 27.

8.

Iejimalides A and B inhibit lysosomal vacuolar H+-ATPase (V-ATPase) activity and induce S-phase arrest and apoptosis in MCF-7 cells.

McHenry P, Wang WL, Devitt E, Kluesner N, Davisson VJ, McKee E, Schweitzer D, Helquist P, Tenniswood M.

J Cell Biochem. 2010 Mar 1;109(4):634-42. doi: 10.1002/jcb.22438.

PMID:
20039309
9.
10.

The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma.

Morimura T, Fujita K, Akita M, Nagashima M, Satomi A.

Pediatr Surg Int. 2008 Oct;24(10):1087-94. doi: 10.1007/s00383-008-2229-2.

PMID:
18712525
11.

Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis.

Hadzhieva M, Kirches E, Wilisch-Neumann A, Pachow D, Wallesch M, Schoenfeld P, Paege I, Vielhaber S, Petri S, Keilhoff G, Mawrin C.

Neuroscience. 2013 Jan 29;230:94-101. doi: 10.1016/j.neuroscience.2012.11.021. Epub 2012 Nov 20.

PMID:
23178912
12.

The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, Wagner E, Müller R, Scita G, Vollmar AM.

Cancer Res. 2012 Nov 15;72(22):5976-87. doi: 10.1158/0008-5472.CAN-12-1772. Epub 2012 Sep 17.

13.

Increase in secretion of glial cell line-derived neurotrophic factor from glial cell lines by inhibitors of vacuolar ATPase.

Nishiguchi M, Tokugawa K, Yamamoto K, Akama T, Nozawa Y, Chaki S, Ueki T, Kameo K, Okuyama S.

Neurochem Int. 2003 May;42(6):493-8.

PMID:
12547648
14.

Synthesis and V-ATPase inhibition of simplified lobatamide analogues.

Shen R, Lin CT, Bowman EJ, Bowman BJ, Porco JA Jr.

Org Lett. 2002 Sep 5;4(18):3103-6.

PMID:
12201727
15.

Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection.

Müller KH, Spoden GA, Scheffer KD, Brunnhöfer R, De Brabander JK, Maier ME, Florin L, Muller CP.

Antimicrob Agents Chemother. 2014 May;58(5):2905-11. doi: 10.1128/AAC.02284-13. Epub 2014 Mar 10.

16.

Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.

Lebreton S, Jaunbergs J, Roth MG, Ferguson DA, De Brabander JK.

Bioorg Med Chem Lett. 2008 Nov 15;18(22):5879-83. doi: 10.1016/j.bmcl.2008.07.003. Epub 2008 Jul 5.

18.

Metabolic capacity regulates iron homeostasis in endothelial cells.

Carraway MS, Suliman HB, Madden MC, Piantadosi CA, Ghio AJ.

Free Radic Biol Med. 2006 Dec 1;41(11):1662-9. Epub 2006 Sep 9.

PMID:
17145554
19.

Inhibitors of vacuolar-type H(+)-ATPase suppresses proliferation of cultured cells.

Manabe T, Yoshimori T, Henomatsu N, Tashiro Y.

J Cell Physiol. 1993 Dec;157(3):445-52.

PMID:
8253855
20.

Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.

Jiang XP, Elliott RL, Head JF.

Anticancer Res. 2010 Mar;30(3):759-65.

PMID:
20392994
Items per page

Supplemental Content

Write to the Help Desk